Recombinant Tissue Factor Pathway Inhibitor in Severe Community-acquired Pneumonia: A Randomized TrialRichard G. Wunderink, Steven M. Opal, Sung Chul Hwang et al.|American Journal of Respiratory and Critical Care Medicine|2011Cited by 128
Temocillin (6 g daily) in critically ill patients: continuous infusion versus three times daily administrationPierre-François Laterre, Thierry Dugernier, Xavier Wittebole et al.|Journal of Antimicrobial Chemotherapy|2014Cited by 87
A mechanism-based prognostic enrichment strategy for the development of the TREM-1 inhibitor nangibotide in septic shockBruno François, Derek C. Angus, Ricard Ferrer et al.|Intensive Care Medicine|2025Cited by 5
Cytomegalovirus Blood DNAemia in Patients with Severe SARS-CoV-2 PneumoniaJean-Baptiste Mesland, Ludovic Gérard, Christine Collienne et al.|Infectious Disease Reports|2025Cited by 1